Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 7:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 94 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Methylcellulose Clear all
Completed Phase 2 Interventional Results available

North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

NCT01408030
View directory record Official record
Conditions
Telangiectasia, Hereditary Hemorrhagic, Epistaxis
Interventions
Sterile saline, Bevacizumab, Estriol, Tranexamic Acid
Drug
Lead sponsor
James Gossage
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Los Angeles, California • Augusta, Georgia • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Sep 4, 2026, 7:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme

NCT02078648
View directory record Official record
Conditions
Adult Brain Glioblastoma, Glioblastoma Multiforme
Interventions
SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose), Bevacizumab, SL-701 + GM-CSF, Imiquimod
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 4, 2026, 7:27 AM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of MCAM in Healthy Adult Participants

NCT07602335
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Placebo, MCAM
Other · Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 4, 2026, 7:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Exploratory Rectal Safety Study of Three Tenofovir Gel Formulations

NCT01575418
View directory record Official record
Conditions
HIV Prevention
Interventions
Rectal formulation (RF) of tenofovir 1% gel, Vaginal formulation (VF) of tenofovir 1% gel, Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel, Radiolabeling of study drugs and semen
Drug · Radiation
Lead sponsor
Ian McGowan
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Sep 4, 2026, 7:27 AM EDT
Completed Phase 4 Interventional Results available

Gabapentin for Pain Control After Osmotic Dilator Insertion and Prior to D&E Procedure: a Randomized Controlled Trial

NCT03080493
View directory record Official record
Conditions
Abortion, Induced, Cervical Preparation, Pain
Interventions
Gabapentin 600mg, Placebo oral capsule, acetaminophen/codeine and ibuprofen
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Female only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Sep 4, 2026, 7:27 AM EDT
Terminated Not applicable Interventional Results available

Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells

NCT00478036
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Acular LS, Pred Forte, Refresh Tears
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Sep 4, 2026, 7:27 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effect of Sage Extract Supplementation on Cognitive Function in Middle-Aged Men and Women

NCT07757529
View directory record Official record
Conditions
Cognitive Ability, General
Interventions
SageXtra, Placebo
Dietary Supplement
Lead sponsor
ESM Technologies, LLC
Industry
Eligibility
40 Years to 60 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 4, 2026, 7:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of YJ001 in Healthy Volunteers

NCT05451667
View directory record Official record
Conditions
Safety and Tolerability
Interventions
YJ001 for Spray Use, Placebo of YJ001 for Spray Use
Drug
Lead sponsor
Yuejia Pharmaceuticals (USA), Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 4, 2026, 7:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Development of Adherence Biomarkers for Multiple Microbicide and Multipurpose Prevention Technology (MPT) Dosage Forms

NCT02569697
View directory record Official record
Conditions
HIV
Interventions
HEC Placebo gel, Placebo Intravaginal Ring, Placebo Vaginal Film, Placebo Vaginal Insert
Other
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Sep 4, 2026, 7:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Epithelial Healing and Visual Outcomes Using Omega-3 Therapy Before and After Photorefractive Keratectomy (PRK) Surgery

NCT01059019
View directory record Official record
Conditions
Refractive Error
Interventions
Omega-3 Fatty Acid Supplements
Dietary Supplement
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 28 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Sep 4, 2026, 7:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Long-term Effects of Oceanix™ on Resistance Training Adaptations

NCT04136821
View directory record Official record
Conditions
Oxidative Stress, Muscle Strength, Resistance Training, Body Composition, Muscle Damage
Interventions
Oceanix, Resistance Training
Dietary Supplement · Other
Lead sponsor
Applied Science & Performance Institute
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Sep 4, 2026, 7:27 AM EDT
Completed Phase 3 Interventional Results available

Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil

NCT03399604
View directory record Official record
Conditions
Primary Pulmonary Hypertension
Interventions
LIQ861 Inhaled Treprostinil
Drug
Lead sponsor
Liquidia Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
38
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Sep 4, 2026, 7:27 AM EDT
Recruiting Phase 2 Interventional

Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations

NCT03786796
View directory record Official record
Conditions
Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Kidney Cancer, Renal Carcinoma, Kidney Cancer Metastatic
Interventions
Olaparib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 4, 2026, 7:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dry Eye Disease Study With Brimonidine

NCT03418727
View directory record Official record
Conditions
Dry Eye
Interventions
Brimonidine, Brimonidine Mono Therapy, sodium carboxymethylcellulose, Corticosteroid Eye Drop
Drug
Lead sponsor
Ocugen
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Hoffman Estates, Illinois • Yorkville, Illinois • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Sep 4, 2026, 7:27 AM EDT
Recruiting Early Phase 1 Interventional

Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa

NCT06058520
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Fecal Microbiota - lyophilized, Placebo drug
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 4, 2026, 7:27 AM EDT
Completed Phase 4 Interventional Results available

Assessment of Alcon's Ocular Image Quantification System

NCT01282138
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol), Dextran 70 0.1%, hydroxypropyl methylcellulose 0.3% (Tears Naturale II)
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Sep 4, 2026, 7:27 AM EDT
Active, not recruiting No phase listed Observational

Impact of GABA Probiotic Lactiplantibacillus Plantarum Lp815 on Sleep Outcomes in Participants with Self-Reported Sleep Disturbance

NCT06789718
View directory record Official record
Conditions
Insomnia (moderate)
Interventions
GABA Probiotic Lactiplantibacillus plantarum Lp815 (5 Billion cfu/dose), Placebo, Optional Sub-Study: Neurotransmitter Urine Test
Dietary Supplement · Other · Diagnostic Test
Lead sponsor
Verb Biotics LLC
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Sep 4, 2026, 7:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Quercetin's Effect on Bone Health and Inflammatory Markers

NCT05371340
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Quercetin (500 mg), Placebo (500 mg)
Dietary Supplement · Other
Lead sponsor
Kennesaw State University
Other
Eligibility
45 Years to 75 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Kennesaw, Georgia
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Sep 4, 2026, 7:27 AM EDT
Completed Phase 4 Interventional Results available

Bioequivalence of Ethylenediamine Dihydrochloride Study

NCT01798589
View directory record Official record
Conditions
Allergic Contact Dermatitis
Interventions
Ethylenediamine dihydrochloride allergen patch
Drug
Lead sponsor
Allerderm
Industry
Eligibility
18 Years to 99 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Sep 4, 2026, 7:27 AM EDT
Completed Phase 2 Interventional Results available

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

NCT01336634
View directory record Official record
Conditions
Cancer
Interventions
Dabrafenib, Trametinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
15
States / cities
Los Angeles, California • Orange, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 4, 2026, 7:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Antioxidant Supplementation on Multiple Endurance Race Performance, Physiology, and Recovery.

NCT04314596
View directory record Official record
Conditions
Oxidative Stress, Muscle Strength, Resistance Training, Body Composition, Muscle Damage
Interventions
Cross Training Course, Oceanix
Other · Dietary Supplement
Lead sponsor
Applied Science & Performance Institute
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Sep 4, 2026, 7:27 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis

NCT01732757
View directory record Official record
Conditions
Conjunctivitis, Allergic
Interventions
Alcaftadine 0.25%, Olopatadine 0.2%, dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
Drug
Lead sponsor
Allergan
Industry
Eligibility
10 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Sep 4, 2026, 7:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy and Safety of Hemp-derived, Full Spectrum Cannabigerol (CBG) in Adults

NCT05743985
View directory record Official record
Conditions
Health, Subjective, Inflammatory Response, Adverse Effect, Side Effect
Interventions
Cannabigerol
Other
Lead sponsor
Formula30A LLC
Industry
Eligibility
21 Years and older
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
5
States / cities
Arlington, Texas • Denton, Texas • Edinburg, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Sep 4, 2026, 7:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of the Inno Cleanse Dietary Supplement on Gut Health and Associated Variables in Healthy Men and Women

NCT07215351
View directory record Official record
Conditions
Constipation, Bloating
Interventions
Dietary supplement for digestive health, placebo capsule
Dietary Supplement
Lead sponsor
University of Memphis
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 4, 2026, 7:27 AM EDT